NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) Is Up 12.1% After PALSONIFY EU Nod And Surging Q1 Revenue Shift
In early May 2026, Crinetics Pharmaceuticals reported first-quarter revenue of about US$10.73 million, up sharply from roughly US$0.36 million a year earlier, alongside a wider net loss of about US$127.85 million and basic loss per share of US$1.23.
Shortly before these results, the European Commission approved PALSONIFY (paltusotine) as the first once-daily oral therapy for adult acromegaly across the EU and EEA, reinforcing Crinetics’ shift into a commercial-stage rare disease business...